Trial description:
A Phase 3, Global, Multi-Centre, Double-Blind, Randomised, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Contact name:
Dr Lizzie Smyth
Trial start date:
Friday, September 4, 2020
Trial end date:
Monday, February 14, 2022
Trial tumour type:
Oesophageal
Show on Radiotherapy:
No
